循环肿瘤细胞检测技术

doi:10.3760/cma.j.issn.1673-422X.2016.05.012

摘要/Abstract

摘要： 循环肿瘤细胞（CTC）检测在肿瘤患者的实时个体化医疗中具有独特的优势。外周血中CTC稀少而又异质，这成为CTC研究的主要技术挑战。CTC检测技术往往首先利用细胞的物理性质或生物学特性等分离富集CTC，再进行基因型或表型分析等以计数CTC或鉴定其分子特征。单细胞分子分析的进展使CTC检测能够提供更准确全面的信息。CTC侵袭转移时上皮间质转化和聚集成簇等生物进程是促进CTC检测的临床应用需要考虑的问题。

关键词: 肿瘤循环细胞, 检测技术, 上皮间质转化

Abstract: Circulating tumor cells (CTCs) detections have unique advantages in the realtime personalized medicine of patients with tumors. The rarity and heterogeneity of CTCs in peripheral blood pose great technical challenge for CTCs researches. Most of technologies for detecting CTCs have been developed to enrich CTCs by virtue of physical properties or specific biological features of the cells at first, then genotype or phenotype analysis are performed to count or characterize CTCs. Advances in molecular analysis of single cells enable CTCs detections to provide more accurate and comprehensive information. Biological processes during CTCs invasion and metastasis such as epithelialmesenchymal transition and clustering should to be considered seriously to promote the clinical applications of CTCs detection.

Key words: Neoplasms circulating cells, Detection technology, Epithelialmesenchymal transition

李树玲，刘晶，魏文青. 循环肿瘤细胞检测技术[J]. 国际肿瘤学杂志, 2016, 43(5): 368-371.

Li Shuling, Liu Jing, Wei Wenqing. Detection technologies of circulating tumor cells[J]. Journal of International Oncology, 2016, 43(5): 368-371.

参考文献

［1］ Yu M, Bardia A, Aceto N, et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility［J］. Science, 2014, 345(6193): 216-220. DOI: 10.1126/science.1253533. ［2］ Krebs MG, Metcalf RL, Carter L, et al. Molecular analysis of circulating tumour cellsbiology and biomarkers［J］. Nat Rev Clin Oncol, 2014, 11(3): 129-144. DOI: 10.1038/nrclinonc.2013.253. ［3］ Reyes EE, Vanderweele DJ, Isikbay M, et al. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castrationresistant prostate cancer［J］. J Transl Med, 2014, 12: 313. DOI: 10.1186/s129670140313z. ［4］ Huang CH, Wick JA, Sittampalam GS, et al. A multicenter pilot study examining the role of circulating tumor cells as a bloodbased tumor marker in patients with extensive smallcell lung cancer［J］. Front Oncol, 2014, 4: 271. DOI: 10.3389/fonc.2014.00271. eCollection 2014. ［5］ Toss A, Mu Z, Fernandez S, et al. CTC enumeration and characterization: moving toward personalized medicine［J］. Ann Transl Med, 2014, 2(11): 108. DOI: 10.3978/j.issn.23055839.2014.09.06. ［6］ Harouaka R, Kang Z, Zheng SY, et al. Circulating tumor cells:advances in isolation and analysis, and challenges for clinical applications［J］. Pharmacol Ther, 2014, 141(2): 209-221. DOI: 10.1016/j.pharmthera.2013.10.004. ［7］ Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigendependent and independent sorting of rare circulating tumor cells［J］. Sci Transl Med, 2013, 5(179): 179ra47. DOI: 10.1126/scitranslmed.3005616. ［8］ SaucedoZeni N, Mewes S, Niestroj RA, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire［J］. Int J Oncol, 2012, 41(4): 1241-1250. DOI: 10.3892/ijo.2012.1557. ［9］ Marrinucci D, Bethel K, Kolatkar A, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers［J］. Phys Biol, 2012, 9(1): 016003. DOI: 10.1088/14783975/9/1/016003. ［10］ Stott SL, Lee RJ, Nagrath S, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer［J］. Sci Transl Med, 2010, 2(25): 25ra23. DOI: 10.1126/scitranslmed.3000403. ［11］ Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial［J］. Clin Cancer Res, 2010, 16(9): 2634-2645. DOI: 10.1158/10780432.CCR092042. ［12］ AlixPanabières C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients［J］. Recent Results Cancer Res, 2012, 195: 69-76. DOI: 10.1007/9783642281600_6. ［13］ Andreopoulou E, Yang LY, Rangel KM, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/DetectTM versus Veridex CellSearchTM system［J］. Int J Cancer, 2012, 130(7): 1590-1597. DOI: 10.1002/ijc.26111. ［14］ Strati A, KasimirBauer S, Markou A, et al. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer［J］. Breast Cancer Res, 2013, 15(2): R20. DOI: 10.1186/bcr3395. ［15］ Sieuwerts AM, Mostert B, BoltDe Vries JA, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients［J］. Clinical Cancer Research, 2011, 17(11): 3600-3618. DOI: 10.1158/10780432.CCR110255. ［16］ Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by ArrayCGH and nextGeneration sequencing［J］. Cancer Res, 2013, 73(10): 2965-2975. DOI: 10.1158/00085472.CAN124140. ［17］ Ramskld D, Luo SJ, Wang YC, et al. Fulllength mRNASeq from singlecell levels of RNA and individual circulating tumor cells［J］. Nat Biotechnol, 2012, 30(8): 777-782. DOI: 10.1038/nbt.2282. ［18］ Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis［J］. Cell, 2014, 158(5): 1110-1122. DOI: 10.1016/j.cell.2014.07.013. ［19］ Cho EH, Wendel M, Luttgen M, et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors［J］. Phys Biol, 2012, 9(1): 016001. DOI: 10.1088/14783975/9/1/016001. ［20］ Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition［J］. Science, 2013, 339(6119): 580-584. DOI: 10.1126/science.1228522.

[1]	牛瑞琪, 刘萍萍, 杜瀛瀛. 早期非小细胞肺癌术后微小残留病灶检测技术与应用进展[J]. 国际肿瘤学杂志, 2022, 49(10): 623-626.
[2]	阎星羽, 廉振颖, 刁玉涛, 刘红艳. BMXΔN通过ERK/MAPK信号通路影响肺癌细胞对吉非替尼的耐药性[J]. 国际肿瘤学杂志, 2021, 48(6): 328-334.
[3]	赵丽丽, 赵文文, 冯青青, 赵文飞, 张雪, 井文君, 魏红梅. 沉默PD-L1表达对胃癌细胞生物学行为的影响[J]. 国际肿瘤学杂志, 2021, 48(12): 705-710.
[4]	王宁菊, 陈冬梅, 章恒, 胡萍, 王燕. 靶向沉默PRL-3基因对肺癌细胞增殖、迁移、侵袭及上皮间质转化的影响[J]. 国际肿瘤学杂志, 2021, 48(1): 18-23.
[5]	王丽丽, 赵松, 欧阳明玥, 谢晓冬, 邢思宁, 刘硕, 于卉影. 多西他赛诱导的多倍体肿瘤细胞在肿瘤复发中的作用[J]. 国际肿瘤学杂志, 2020, 47(6): 340-345.
[6]	陈罗军，李娜，田景媛，宋启斌，于金明. 循环肿瘤细胞在临床应用中的研究进展[J]. 国际肿瘤学杂志, 2018, 45(8): 552-555.
[7]	邹江, 郭晓兰. 液体活检在肿瘤诊治中的研究进展[J]. 国际肿瘤学杂志, 2018, 45(2): 107-111.
[8]	汪熠，苏晓三. 肿瘤细胞来源的外泌体在肿瘤转移中的作用及其机制[J]. 国际肿瘤学杂志, 2018, 45(11): 681-684.
[9]	李艳，陈琼霞，王绪明. 敲低Stat5对甲状腺癌TT细胞侵袭及上皮间质转化的影响[J]. 国际肿瘤学杂志, 2018, 45(1): 1-.
[10]	于华杰，韩露，欧洋，李胜，高德海. 荧光在循环肿瘤细胞鉴定中的应用[J]. 国际肿瘤学杂志, 2018, 45(1): 35-.
[11]	李文清,侯劲松. 上皮间质转化的表观遗传调控[J]. 国际肿瘤学杂志, 2017, 44(12): 918-921.
[12]	李晓晴,李袁飞. 结肠癌上皮间质转化信号通路机制研究[J]. 国际肿瘤学杂志, 2016, 43(5): 385-386.
[13]	陈少华,钱军. 上皮间质转化与肿瘤干细胞的关系[J]. 国际肿瘤学杂志, 2016, 43(1): 36-38.
[14]	李浩；李胜；张百江. 循环肿瘤细胞检测在非小细胞肺癌中的应用[J]. 国际肿瘤学杂志, 2015, 42(4): 298-300.
[15]	倪婷, 王玉东. 肿瘤细胞弥散机制及循环肿瘤细胞的检测和临床应用[J]. 国际肿瘤学杂志, 2015, 42(11): 841-844.